Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Ligand Pharmaceuticals (Nasdaq: LGND) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. CEO Todd Davis and CFO Tavo Espinoza will deliver a presentation on February 11, 2025, at 2:40 p.m. Eastern Time.

The company's management team will be available for one-on-one meetings with investors and conference attendees. Interested investors can arrange meetings through their Oppenheimer representative.

JUPITER, Fla.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025 at 2:40 p.m. Eastern Time.

Ligand management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Oppenheimer representative.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250206792261/en/

Investors:

Melanie Herman

investors@ligand.com

(858) 550-7761

Media:

Kellie Walsh

media@ligand.com

(914) 315-6072

Source: Ligand Pharmaceuticals Incorporated

FAQ

When is Ligand (LGND) presenting at the Oppenheimer Healthcare Conference 2025?

Ligand (LGND) will present at the Oppenheimer Healthcare Conference on February 11, 2025, at 2:40 p.m. Eastern Time.

Who will represent LGND at the Oppenheimer Healthcare Conference 2025?

CEO Todd Davis and CFO Tavo Espinoza will represent Ligand Pharmaceuticals at the conference.

How can investors schedule meetings with LGND management at the Oppenheimer conference?

Investors interested in one-on-one meetings with Ligand management should contact their Oppenheimer representative to arrange meetings.

What type of investor meetings will LGND offer at the Oppenheimer Healthcare Conference?

Ligand management will offer one-on-one meetings with investors and conference attendees during the event.